GlassScriptPhysician profile
Irini E Veronikis
NPI 1578508701
$4,877.24
in general payments reported to CMS, 2019-2025
39 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $65.62 · 2021: $98.37 · 2022: $324 · 2023: $886 · 2024: $1,341 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,194 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,193.89 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $628.40 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $605.34 | 2019-2025 | Freestyle Libre 3, Eterna |
| Novo Nordisk INC | $486.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $352.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sequel Med Tech, LLC | $257.52 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $229.35 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $225.84 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $190.95 | 2023-2025 | |
| Medtronic, INC. | $146.12 | 2023-2025 | Minimed 780g, Vanta Adaptivestim |
| Radius Health, INC. | $117.42 | 2024-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $111.87 | 2020-2025 | |
| Acella Pharmaceuticals, LLC | $110.26 | 2023-2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $104.72 | 2023-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $101.10 | 2021-2025 | Strensiq |
| Mannkind Corporation | $99.41 | 2023-2025 | Afrezza |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.54 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Almatica Pharma LLC | $90.17 | 2024-2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $87.14 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $84.91 | 2025 | Unithroid |
| Corcept Therapeutics | $70.19 | 2023-2025 | Korlym |
| Madrigal Pharmaceuticals | $69.77 | 2025 | Rezdiffra |
| Abbvie INC. | $62.78 | 2025 | |
| Averitas Pharma INC. | $61.09 | 2024 | Qutenza |
| Tandem Diabetes Care, INC. | $57.69 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $56.70 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amphastar Pharmaceuticals, INC. | $54.06 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $52.55 | 2024-2025 | Tlando |
| Ibsa Pharma INC. | $50.65 | 2021-2025 | Licart, Tirosint, Flector |
| Nevro Corp. | $31.07 | 2023 | Senza |
| Chiesi USA, INC. | $27.55 | 2024 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $24.83 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $21.90 | 2025 | |
| Ascensia Diabetes Care US INC. | $19.00 | 2021 | |
| Horizon Therapeutics Plc | $18.68 | 2019 | |
| Antares Pharma, INC. | $17.84 | 2025 | Xyosted |
| Kyowa Kirin, INC. | $17.47 | 2024 | Crysvita |
| Clarus Therapeutics INC. | $15.71 | 2021 | |
| Medtronic Minimed, INC. | $13.72 | 2019 | |
| Insulet Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irini Veronikis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.